Peptide · developed by Regeneron Pharmaceuticals
Olatorepatide (HS-20094) is a drug studied in hidradenitis suppurativa, with overweight and obesity also listed as trial conditions.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07830329 | Phase 2 | Hidradenitis Suppurativa | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hidradenitis Suppurativa
Updated Nov 22, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →